European Regulatory Perspective on Super-Generics: Antacid Orally Disintegrating Tablets (ODT)
Abstract
Abstract
Super-generic is the general form of nomenclature for hybrid medicinal product in European Union (EU). The super-generic form of the medicinal product is one that considers changes in the form of active substance, therapeutic indications, strength, pharmaceutical form or route of administration. They rely partly on results of preclinical tests and clinical trials of an innovator product and also on new data with appropriate bioavailability and bioequivalence studies. Marketing authorization for super-generics in EU can be obtained by any of the four registration processes, i.e., centralized, decentralized, mutual recognition and national procedure. Additional studies such as pharmacokinetics, preclinical and clinical studies are conducted as required by the changes that are made in the super-generic product as compared to the innovator product. Antacid orally disintegrating tablets (ODTs) as a part of super-generics have gained considerable attention since last decade. This mode of administration is expected to be beneficial to pediatric, geriatric patients or people with impaired swallowing especially psychiatric patients. These products have a significant impact on exhausting marketing authorization trend of conventional dosage forms. In an effort to develop drug products that are more convenient to use and address potential issues of patient compliance, super-generics have gained importance.
Keywords: super-generic, orally disintegrating tablet (ODT), antacid, patient compliance
Cite this Article
Jain A, Dixit M, Samaga V et al. European regulatory perspective on super-generics: Antacid orally disintegrating tablets (ODT). Trends in Drug Delivery. 2016; 3(1): 31–37p.
Downloads
Additional Files
Published
Issue
Section
License
Copyright Transfer and Declaration Form (Please compile this form, sign and send by e-mail and post)
Journal Title:
Title of the Paper:
Corresponding Author’s Information: Name: Address:
E-mail:
Contact Number: I
t is herein agreed that: The copyright to the above-listed unpublished and original article is transferred to STM Journals. This copyright transfer covers the exclusive right to reproduce and distribute the contribution, including reprints, translations, photographic reproductions, microform, electronic form (offline, online), or any other reproductions of similar nature. I/We declare that above manuscript is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere. I/ We warrant(s) that his/her/their contribution is original, except for such excerpts from copyrighted works as may be included with the permission of the copyright holder and author thereof, that it contains no libelous statements, and does not infringe on any copyright, trademark, patent, statutory right, or propriety right of others. I/We will not publish his/her/their above said contribution anywhere else without the prior written permission of the publisher unless it has been changed substantially.I/We also agree to the authorship of the article in the following order:Author(s) Name Signature(s)1. ________________2. ________________3. ________________4. ________________The author(s) agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal (comments if any to the editor can be added below).
